WallStSmart

Airsculpt Technologies Inc (AIRS)vsFresenius Medical Care Corporation (FMS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 12649% more annual revenue ($19.36B vs $151.84M). FMS leads profitability with a 4.9% profit margin vs -7.4%. FMS earns a higher WallStSmart Score of 50/100 (C-).

AIRS

Avoid

34

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.3Quality: 3.5
Piotroski: 2/9Altman Z: 0.75

FMS

Buy

50

out of 100

Grade: C-

Growth: 2.7Profit: 5.0Value: 9.3Quality: 6.0
Piotroski: 6/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AIRSUndervalued (+11.7%)

Margin of Safety

+11.7%

Fair Value

$2.40

Current Price

$5.11

$2.71 discount

UndervaluedFair: $2.40Overvalued
FMSUndervalued (+69.0%)

Margin of Safety

+69.0%

Fair Value

$77.65

Current Price

$22.03

$55.62 discount

UndervaluedFair: $77.65Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AIRS1 strengths · Avg: 10.0/10
EPS GrowthGrowth
200.0%10/10

Earnings expanding 200.0% YoY

FMS3 strengths · Avg: 9.3/10
P/E RatioValuation
11.9x10/10

Attractively priced relative to earnings

Price/BookValuation
0.8x10/10

Reasonable price relative to book value

PEG RatioValuation
0.798/10

Growing faster than its price suggests

Areas to Watch

AIRS4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

Market CapQuality
$382.36M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-11.2%2/10

ROE of -11.2% — below average capital efficiency

FMS4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Return on EquityProfitability
7.1%3/10

ROE of 7.1% — below average capital efficiency

Profit MarginProfitability
4.9%3/10

4.9% margin — thin

Revenue GrowthGrowth
-5.5%2/10

Revenue declined 5.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : AIRS

The strongest argument for AIRS centers on EPS Growth.

Bull Case : FMS

The strongest argument for FMS centers on P/E Ratio, Price/Book, PEG Ratio. PEG of 0.79 suggests the stock is reasonably priced for its growth.

Bear Case : AIRS

The primary concerns for AIRS are Revenue Growth, Market Cap, Piotroski F-Score.

Bear Case : FMS

The primary concerns for FMS are Altman Z-Score, Return on Equity, Profit Margin. Thin 4.9% margins leave little buffer for downturns.

Key Dynamics to Monitor

AIRS profiles as a turnaround stock while FMS is a value play — different risk/reward profiles.

AIRS carries more volatility with a beta of 2.02 — expect wider price swings.

AIRS is growing revenue faster at 0.0% — sustainability is the question.

FMS generates stronger free cash flow (37M), providing more financial flexibility.

Bottom Line

FMS scores higher overall (50/100 vs 34/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Airsculpt Technologies Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Airsculpt Technologies Inc (AIRS) is a pioneering company in the aesthetic medical technology sector, renowned for its innovative AirSculpt® procedure that delivers minimally invasive body contouring with a strong commitment to patient safety and comfort. The company is strategically expanding its network of licensed practitioners, supported by a robust focus on technological advancements, which positions Airsculpt favorably within the rapidly growing non-invasive cosmetic treatment market. As consumer demand for aesthetic solutions continues to rise globally, Airsculpt is well-positioned to enhance its market share and diversify its service offerings, aiming to achieve substantial growth and sustainable value for its investors.

Visit Website →

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

Want to dig deeper into these stocks?